Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes

Stroke. 2009 Feb;40(2):597-603. doi: 10.1161/STROKEAHA.108.519801. Epub 2008 Nov 20.

Abstract

Background and purpose: We examined the possibility that activation of the human brain renin-angiotensin system is involved in enhancement of ischemic brain damage using chimeric transgenic mice with human renin (hRN) and human angiotensinogen (hANG) genes.

Methods: Chimeric (hRN/hANG-Tg) mice were generated by mating of hRN and hANG transgenic mice. Permanent occlusion of the middle cerebral artery (MCA) by an intraluminal filament technique induced focal ischemic brain lesions.

Results: hRN/hANG-Tg mice showed higher angiotensin II levels in the plasma and brain. The ischemic brain area at 24 hours after MCA occlusion was significantly enlarged in hRN/hANG-Tg mice with an enhanced neurological deficit compared to that in wild-type, hRN-Tg and hANG-Tg mice. The reduction of cerebral blood flow in the periphery region of the MCA territory after MCA occlusion was markedly exaggerated in hRN/hANG-Tg mice. Superoxide anion production in the brain and arteries was also increased significantly in hRN/hANG-Tg mice even before MCA occlusion and was further enhanced after MCA occlusion. Treatment with an AT(1) receptor blocker, valsartan (3.0 mg/kg per day), for 2 weeks significantly reduced the ischemic brain area and improved the neurological deficit after MCA occlusion in hRN/hANG-Tg mice, similar to those in wild-type, hRN-Tg, and hANG-Tg mice, with restoration of cerebral blood flow in the peripheral region and decreases in superoxide anion production and blood pressure.

Conclusions: These results indicate that activation of the human renin-angiotensin system exaggerates ischemic brain damage mainly through stimulation of the AT(1) receptor and marked reduction of cerebral blood flow and enhanced oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / metabolism
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensinogen / genetics*
  • Animals
  • Brain Chemistry / genetics
  • Brain Chemistry / physiology
  • Brain Ischemia / drug therapy
  • Brain Ischemia / genetics*
  • Brain Ischemia / pathology*
  • Capillaries / pathology
  • Cerebrovascular Circulation
  • Humans
  • Infarction, Middle Cerebral Artery / pathology
  • Male
  • Mice
  • Mice, Transgenic
  • Oxidative Stress / physiology
  • Receptor, Angiotensin, Type 1 / biosynthesis
  • Receptor, Angiotensin, Type 1 / genetics
  • Receptor, Angiotensin, Type 2 / biosynthesis
  • Receptor, Angiotensin, Type 2 / genetics
  • Renin / genetics*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Superoxides / metabolism
  • Tetrazoles / pharmacology
  • Valine / analogs & derivatives
  • Valine / pharmacology
  • Valsartan

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Tetrazoles
  • Angiotensinogen
  • Superoxides
  • Angiotensin II
  • Valsartan
  • Renin
  • Valine